SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart

Abstract Background Hyperglycaemia associated with myocardial oxidative stress and fibrosis is the main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor has recently been reported to improve glycaemic control in patients with type 2 diabetes in an i...

Full description

Bibliographic Details
Main Authors: Chenguang Li, Jie Zhang, Mei Xue, Xiaoyu Li, Fei Han, Xiangyang Liu, Linxin Xu, Yunhong Lu, Ying Cheng, Ting Li, Xiaochen Yu, Bei Sun, Liming Chen
Format: Article
Language:English
Published: BMC 2019-02-01
Series:Cardiovascular Diabetology
Subjects:
Type 2 diabetes mellitus
SGLT2
Empagliflozin
Oxidative stress
Myocardial fibrosis
Online Access:http://link.springer.com/article/10.1186/s12933-019-0816-2

Internet

http://link.springer.com/article/10.1186/s12933-019-0816-2

Similar Items